☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
durvalumab
AstraZeneca's Imfinzi (durvalumab) Receives EC's Approval as 1L Treatment for Extensive-Stage Small Cell Lung Cancer
September 2, 2020
AstraZeneca's Imfinzi (durvalumab) Receives MHLW's Approval for Extensive-Stage Small Cell Lung Cancer
August 21, 2020
AstraZeneca's Imfinzi (durvalumab) Receives the US FDA's Priority Review for Less Frequent Fixed-Dose Use in NSCLC and Bladder Can...
August 18, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.